The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of FcgRIIIA single nucleotide polymorphisms (SNPs) on the efficacy of IgG1 monoclonal antibodies (mAbs) in PANGEA study patients (pts) with advanced gastroesophageal adenocarcinoma (aGEA).
 
Anthony Serritella
No Relationships to Disclose
 
Bryan Peterson
No Relationships to Disclose
 
Katherine I. Zhou
No Relationships to Disclose
 
Nicole Arndt
No Relationships to Disclose
 
Daniela Del Gaudio
No Relationships to Disclose
 
Kelly Arndt
No Relationships to Disclose
 
Soma Das
No Relationships to Disclose
 
Samuel J Klempner
Stock and Other Ownership Interests - TP Therapeutics
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Foundation Medicine; Lilly; Pieris Pharmaceuticals
Speakers' Bureau - Foundation Medicine
Research Funding - Astellas Pharma (Inst); Leap Therapeutics (Inst)
 
Ping Liu
No Relationships to Disclose
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus